Abstract
Heterozygosity for a mutant dysfunctional C1 inhibitor protein, a member of the serine proteinase inhibitor (serpin) superfamily, results in type II hereditary angioneurotic oedema. We identified a “hinge” region mutation in C1 inhibitor with a Val to Glu replacement at P14 Val–432. Recombinant C1 inhibitors P10 Ala→Thr and P14 Val→Glu did not form stable complexes with fluid phase C1s or kallikrein. The P14 Val→Glu mutant, however, was cleaved to a 96K form by C1s, while the P10 Ala→Thr mutant was not. The recombinant P10 mutant also did not complex with C1s, kallikrein or β–factor XIIa–Sepharose. The two mutations, therefore, result in dysfunction by different mechanisms: in one (P14 Val→Glu), the inhibitor is converted to a substrate, while in the other (P10 Ala→Thr), interaction with target protease is blocked.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Carrell, R.W. & Boswell, D.R., Serpins: The superfamily of serine proteinase inhibitors: in Proteinase inhibitors, (eds Barrett, A. & Salvesen, G.) 403–420 (Elsevier, Amsterdam, 1986).
Schechter, J. & Berger, A. Biochem. Biophys. Res. Commun. 27, 157–162 (1967).
Mathesen, N.R., van Halbeck, H. & Travis, J. J. biol. Chem. 266, 13489–13491 (1991).
Pemberton, P.A., Harrison, R.A., Lachmann, P.J. & Carrell, R.W. Biochem. J. 258, 193–198 (1989).
Carrell, R.W. & Owen, M.C. Nature 317, 730–732 (1985).
Pemberton, P.A., Stein, P.E., Pepys, M.B., Potter, J.M. & Carrell, R.W. Nature 336, 257–258 (1988).
Loebermann, H., Tokuoka, R., Diesenhofer, J. & Huber, R. J. molec. Biol. 177, 531–557 (1984).
Stein, P.E. et al. Nature 347, 99–102 (1990).
Carrell, R.W., Evans, D.L. & Stein, P.E. Nature 353, 576–578 (1991).
Aulak, K.S. et al. Biochem. J. 253, 615–618 (1988).
Skriver, K., Radziejewska, E., Siebermann, J.A., Donaldson, V.H. & Bock, S.C. J. biol. Chem. 264, 3066–3071 (1989).
Aulak, K.S. & Harrison, R.A. J. 271, 565–569 (1990).
Devraj-Kizuk, R. et al. Blood 72, 1518–1523 (1988).
Rijken, D.C., Groeneveld, E., Kluft, C. & Nieuwenhuis, H.K. Biochem. J. 255, 609–615 (1988).
Perry, D.J., Harper, P.L., Fairham, S., Daly, M. & Carrell, R.W. FEBS Lett. 254, 174–176 (1989).
Molho-Sabatier, P. et al. J. clin. Invest. 84, 1236–1242 (1989).
Levy, N.J., Ramesh, N., Cicardi, M., Harrison, R.A. & Davis, III A.E. Proc. natn. Acad. Sci. U.S.A. 87, 265–268 (1990).
Caso, R. et al. Brit. J. Haem. 77, 87–92 (1991).
Skriver, K. et al. J. biol. Chem. 266, 9216–9221 (1991).
Aiach, M. et al. Thromb. Res. 39, 559–570 (1985).
Cugno, M. et al. J. clin. Invest. 85, 1215–1220 (1990).
Rosen, F.S., Alper, C.A., Pensky, J., Klemperer, M.R. & Donaldson, V.H. J. clin. Invest. 50, 2143–2149 (1971).
Donaldson, V.H. et al. Blood 69, 1096–1101 (1987).
Donaldson, V.H. et al. J. clin. Invest. 75, 124–132 (1985).
Harrison, R.A. Biochemistry 22, 5001–5007 (1983).
Laemmli, U.K. Nature 227, 680–685 (1970).
Bing, D.H., Andrews, J.M., Morris, K.M., Cole, E. & Irish, V. Prep. Biochem. 10, 269–296 (1980).
Einstein, L.P., Schneeberger, E.E. & Colten, H.R. J. exp. Med. 143, 114–126 (1976).
Chirgwin, J.M., Przbyla, A.E., MacDonald, R.J. & Rutter, W.J. Biochemistry 18, 5294–5299 (1979).
Bock, S.C. et al. Biochemistry 25, 4292–4301 (1986).
Sanger, F., Nicklen, S. & Coulson, R.A. Proc. natn. Acad. Sci. U.S.A. 74, 5463–5467 (1977).
Katz, Y. & Strunk, R.C. J. Immunol. 142, 2041–2045 (1989).
Cole, F.S., Auerbach, H.S., Goldberg, G. & Colten, H.R. J. Immunol. 134, 2610–2616 (1985).
Eldering, E., Nuijens, J.H. & Hack, C.E. J. biol. Chem. 263, 11776–11779 (1988).
Luthmann, H. & Magnusson, G. Nucleic Acids Res. 5, 1295–1308 (1983).
Nuijens, J.H., Huijbregts, C.C.M., van Mierlo, G.M. & Hack, C.E. mmunology 61, 387–389 (1987).
Harrison, R.A. & Rosen, F.S. Molec. Immunol. 19, 1374 (abstract) (1982).
Holmes, W.E. et al. Science 238, 209–211 (1987).
Parad, R.B., Kramer, J., Strunk, R.C., Rosen, F.S. & Davis, III A.E. Proc. natn. Acad. Sci. U.S.A. 87, 6786–6790 (1990).
Roos, M.H., Mollenhauer, E., Demant, P. & Rittner, C. Nature 298, 854–856 (1982).
Carroll, M.C. et al. Proc. natn. Acad. Sci. U.S.A. 87, 6868–6872 (1990).
de Agostini, A. et al. J. clin. Invest. 82, 700–705 (1988).
Engh, R.A., Wright, H.T. & Huber, R. Protein Engineering 3, 369–477 (1990).
Mottonen, J. et al. Nature 355, 270–273 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davis, A., Aulak, K., Parad, R. et al. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nat Genet 1, 354–358 (1992). https://doi.org/10.1038/ng0892-354
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng0892-354
This article is cited by
-
Angioedema associated with C1 inhibitor deficiency
Clinical Reviews in Allergy & Immunology (1999)
-
Mechanism of Action of Anti-C1-Inhibitor Autoantibodies: Prevention of the Formation of Stable C1s-C1-inh Complexes
Molecular Medicine (1998)
-
Arginine substitutions in the hinge region of antichymotrypsin affect serpin β-sheet rearrangement
Nature Structural & Molecular Biology (1996)
-
What do dysfunctional serpins tell us about molecular mobility and disease?
Nature Structural & Molecular Biology (1995)
-
Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition
Nature Structural & Molecular Biology (1995)